Browse treatments

…Background Immunotherapies have revolutionized cancer care in recent decades, but approved…

…ights that are essential for the rational design of γδTIL-based immunotherapies.…

… function is needed to accelerate development of more effective immunotherapies. However, training a predictive model remains challenging due t…

…wide array of innovative cancer-related technologies, including immunotherapies. Through our funding model, the NCI SBIR program accelerates th…

…This last decade, immunotherapies have shaken up cancer treatment, but only a small percentage of…

…ractory CMV requires alternatives like foscarnet, cidofovir, or immunotherapies. New treatments, such as maribavir, have shown promise for refr…

…r that influences the efficacy of cancer treatments. The use of immunotherapeutic agents has emerged as an important therapeutic strategy in the periope…

…g conjugates (five drugs, 18%), with smaller contributions from chemotherapies, tyrosine kinase inhibitors, and others.Most patients were trea…

…astasis which is associated with a lack of durable responses to immunotherapies. Adoptive cell transfer of autologous tumor-infiltrating lympho…

…Background Atypical tumor response patterns associated with immunotherapies pose significant challenges for assessing treatment response an…

…ted fibroblasts (CAFs) that collectively impede the efficacy of immunotherapies. Although oncolytic viruses (OVs) have demonstrated promising p…

…Background Immunotherapies exhibit class- and target-specific safety challenges, particula…